e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension
M. Levy, F. Bajolle, S. Cohen, D. Bonnet (Paris, France)
Source:
Annual Congress 2009 - Pulmonary arterial hypertension
Session:
Pulmonary arterial hypertension
Session type:
E-Communication Session
Number:
1488
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Levy, F. Bajolle, S. Cohen, D. Bonnet (Paris, France). Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension. Eur Respir J 2009; 34: Suppl. 53, 1488
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: respiratory care for newborns in resource-limited settings
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006
Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension
Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management
Year: 2017
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science
Source: Eur Respir J 2016; 47:1615-1617
Year: 2016
Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006
Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019
Successful artocoronary bypass grafting in a patient with severe idiopathic pulmonary arterial hypertension: use of intravenous treprostinil
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006
Experience with inhaled iloprost in paediatric pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Source: Eur Respir J 2015; 45: 1142-1149
Year: 2015
Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study
Source: Eur Respir J 2012; 39: 772-775
Year: 2012
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
Treatment options for paediatric pulmonary arterial hypertension
Source: Eur Respir Rev 2010 19: 321-330
Year: 2010
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept